LCTX

Business Context and Reporting Period

Company: BioTime, Inc. (Note: Input metadata referenced Lineage Cell Therapeutics, but the filing text identifies the registrant as BioTime, Inc.)
Reporting Period: Quarterly period ended September 30, 2000.
Status: Development stage company engaged in the research and development of synthetic plasma expanders (Hextend), blood volume substitute solutions, and organ preservation solutions. The company has not yet generated significant operating revenues and relies on licensing agreements and equity financing.

Key Financial Metrics

Operating Expenses (Nine Months Ended Sep 30, 2000):
- Research and Development: $2,687,112
- General and Administrative: $1,362,835
- Total Expenses: $4,049,947

Material Changes vs. Prior Period

• Revenue: No revenue was recognized for the three or nine months ended September 30, 2000. This contrasts with the nine months ended September 30, 1999, where $1,037,500 in license fee revenue was recognized. Royalties from product sales are recognized with a lag (e.g., Q3 2000 sales recognized in Q4 2000).
• Net Loss: The net loss for the nine months ended September 30, 2000 ($3.87M) decreased slightly compared to the same period in 1999 ($4.03M).
• Expenses: R&D expenses decreased by approximately $1.08M year-over-year for the nine-month period, attributed to decreased consultant option compensation and the completion of a European clinical trial in 1999. G&A expenses decreased by approximately $134K, primarily due to reduced personnel costs.
• Liquidity: Cash and cash equivalents decreased from $5.29M at December 31, 1999, to $2.02M at September 30, 2000, reflecting a net cash outflow from operating activities of $3.99M for the nine-month period.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management estimates current cash resources ($2.02M) are sufficient to finance operations for approximately ten months. The company expects to incur losses for the foreseeable future and will likely need to curtail product development or secure additional equity/debt financing to continue operations.
• Product Strategy:
  • Hextend: Sold exclusively in the U.S. and Canada by Abbott Laboratories. Sales are in a "ramp-up" phase. Abbott is actively seeking hospital formulary approvals.
  • PentaLyte: Phase I clinical trial completed; data compilation for FDA submission is underway.
  • HetaCool: Development for low-temperature surgery is ongoing; FDA approval required.
• Financing Activity: During September 2000, the company raised approximately $796K through the exercise of warrants and options. Greenbelt Corp. indicated intent to exercise additional warrants in late 2000 and early 2001, potentially raising an additional ~$333K.
• Risks:
  • Dependence on successful clinical trials and regulatory approvals (FDA and foreign).
  • Reliance on Abbott Laboratories for U.S./Canada sales and royalty payments.
  • Need for additional capital; failure to secure financing could force suspension of operations.
  • Competition from existing blood volume expanders and potential generic equivalents.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "ten-month" liquidity estimate given the high burn rate and lack of current revenue.
• Abbott Sales Data: Confirm the timing and magnitude of Hextend sales reports from Abbott, as revenue recognition is delayed by one quarter.
• Regulatory Status: Monitor the status of the Canadian New Drug Submission for Hextend and the Phase I data submission for PentaLyte.
• Financing Plans: Assess the likelihood and terms of future equity offerings, as the company explicitly states additional funds are required.
• Warrant Exercises: Track the execution of the pending warrant exercises by Greenbelt Corp. to confirm the projected cash inflow.